Juanjuan Wang

Juanjuan Wang

Auto-generated profile, based on publicly available information

Juanjuan Wang

The State Key Laboratory of Genetic Engineering, School of Life Science and Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2017 in Oncogene
Verified
Journal Article
Closed access
PDF file
XHX Hu
X Hu
YZY Zhao
Y Zhao
LWL Wei
L Wei
BZB Zhu
B Zhu
DSD Song
D Song
JWJ Wu
J Wu

8 March 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
YZYahui Zhao
Yahui Zhao
XHXiaoding Hu
Xiaoding Hu
LWLi Wei
Li Wei
DSDan Song
Dan Song
JWJuanjuan Wang
Juanjuan Wang
JWJiaxue Wu
Jiaxue Wu

10 July 2017 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JWJuanjuan Wang
Juanjuan Wang
CZChenggang Zhu
Chenggang Zhu
DSDan Song
Dan Song
RXRuiqi Xia
Ruiqi Xia
WYWenbo Yu
Wenbo Yu
JWJiaxue Wu
Jiaxue Wu
Poly(ADP-ribose) polymerases (PARPs) are ADP-ribosylating enzymes and play important roles in a variety of cellular processes. Most small-molecule PARP inhibitors developed to date have been against PARP1, a poly-ADP-ribose transferase, and suffer from poor selectivity. PARP16, a mono-ADP-ribose transferase, has recently emerged as a potential therapeutic target, but its inhibitor development has trailed behind. Here we newly characterized epigallocatechin-3-gallate (EGCG) as a potential inhibitor of PARP16. We found that EGCG was associated with PARP16 and dramatically inhibited its activity in vitro. Moreover, EGCG suppressed the ER stress-induced phosphorylation of PERK and the transcription of unfolded protein response-related genes, leading to dramatically increase of cancer cells apoptosis under ER stress conditions, which was dependent on PARP16. These findings newly characterized EGCG as a potential inhibitor of PARP16, which can enhance the ER stress-induced cancer cell apoptosis, suggesting that a combination of EGCG and ER stress-induced agents might represent a novel approach for cancer therapy or chemoprevention.